drugset / Trial / NCT01811576

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

NCT01811576

Phase 2 Completed 52 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the clinical effect of TV-1106.

Timeline

Start
2013-03-31
Primary completion
2013-08-05
Completion
2013-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ALBUSOMATROPIN Protein / enzyme biologic
Comparator Somatropin Protein / enzyme biologic Subcutaneous

Indications